Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression: A comparative study with CD44

Histopathology

Volumn 34, Issue 1, 1999, Pages 25-34

  Bànkfalvi, À ^d   Terpe, H J ^d   Breukelmann, D ^d   Bier, B ^a   Rempe, D ^d   Pschadka, G ^d   Krech, R ^b   Lelle R J ^d   Boecker, W ^c  

^a Department of Pathology   (Germany)

^b City Hospital   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d NONE

Author keywords

Beta catenin; Breast cancer prognosis; Breast carcinogenesis; E cadherin

Indexed keywords

BETA CATENIN; HERMES ANTIGEN; UVOMORULIN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, CD44; BETA CATENIN; BREAST DISEASES; BREAST NEOPLASMS; CADHERINS; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; SURVIVAL RATE; TRANS-ACTIVATORS;

EID: 0037656881     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00540.x     Document Type: Article

References (39)

1. 1. Günthert U, Stauder R, Mayer B, Terpe HJ. Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv. 1995; 24; 19-41.
2. 2. Smith MEF. Pignatelli M. The molecular histology of neoplasia; the role of the cadherin/catenin complex. Histopathology 1997; 31; 107-111.
3. 3. Bànkfalvi A, Terpe HJ, Breukelmann D et al. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 1998; 33; in press.
4. 4. Lewis JE. Jensen PJ. Johnson KR, Wheelock MJ. E-cadherin mediates adherens junction organisation through protein kinase C. J. Cell. Sci. 1995; 107; 3615-3621.
5. 5. McCrea PD. Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science 1991; 254; 1359-1361.
6. 6. Shimoyana Y, Hirohashi S. Cadherin intercellular adhesion molecule in hepatocellular carcinomas; loss of E-cad expression in an undifferentiated carcinoma. Cancer Lett. 1991; 57; 2185-2191.
7. 7. Mayer B. Johnson JP, Leitl F et al. E-cad expression in primary and metastatic gastric cancer; down regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993; 53; 1690-1695.
8. 8. Kinsella AR, Green B, Lepts GC. Hill CL, Bowie G, Taylor BA. The role of the cell adhesion molecule E-cad in large bowel tumour cell invasion and metastasis. Br. ]. Cancer 1993; 67; 904-909.
9. 9. Umbas R, Isaacs WB, Bringuier PP et al. Decreased E-cad expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994; 54; 3929-3933.
10. 10. Gamallo C. Palacios J, Suarez A et al. Correlation of E-cad expression with differentiation grade and histological type in breast carcinomas. Am. J. Pathol. 1993; 142; 987-993.
11. 11. Charpin C, Garcia S, Bouvier C et al. E-cad quantitative immunocytochemical assays in breast carcinomas. J. Pathol. 1997; 181; 294-300.
12. 12. Hunt NCA, Douglas-Jones AG. Jasani B. Morgan JM. Pignatelli M. Loss of E-cad expression associated with lymph node metastases in small breast carcinomas. Virchows Arch. 1997; 430; 285-289.
13. 13. Oka H, Shiozaki H. Kobajashi K et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993; 53; 1696-1701.
14. 14. Siitonen SM, Kononen JT. Helin HJ. Rantala IS. Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavourable prognosis in breast cancer. Am. J. Clin. Pathol. 1996; 105; 394-401.
15. 15. Moll R, Mitze M, Frixen UH, Birchmeier W. Differential loss of E-cad expression in infiltrating ductal and lobular breast carcinomas. Am. J. Pathol. 1993; 143; 1731-1742.
16. 16. Gupta SK, Douglas-Jones AG. Jasani B, Morgan JM, Pignatelli M, Mansel RE. E-cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch. 1997; 430; 23-28.
17. 17. Berx G, Cleton-Jansen AM, Strumane K et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13; 1919-1925.
18. 18. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77; 1605-1613.
19. 19. Takayama T, Shiozaki H, Shibamoto S et al. β-catenin expression in human cancers. Am. J. Pathol. 1996; 148; 39-46.
20. 20. Pierceall WE, Woodard AS, Morrow JS. Rimm D. Fearon ER. Frequent alterations in E-cadherin and alpha-and beta-catenin expression in human breast cancer cell lines. Oncogene 1995; 11; 1319-1326.
21. 21. Rimm DL. Sinard JH, Morrow JS. Reduced α-catenin and E-cadherin expression in breast cancer. Lab. Invest. 1995; 75; 506-512.
22. 22. Candidus S. Bischoff P, Becker KF, Höfler H. No evidence for mutation in the alpha-and beta-catenin genes in human gastric and breast carcinomas. Cancer Res. 1996; 56; 49-52.
23. 23. Rubinfeld B, Souza B, Albert I et al. Association of the APC gene product with α-catenin. Science 1993; 262; 1731-1734.
24. 24. De Leeuw WJF. Berx G, Vos CBJ et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J. Pathol. 1997; 183; 404-411.
25. 25. Hashizume R, Koizumi H, Ihara A, Ohta T, Uchikoshi T. Expression of α-catenin in normal breast tissue and breast carcinoma; a comparative study with epithelial cadherin and α-catenin. Histopathology 1996; 29; 139-146.
26. 26. Sloane JP, Amendoeira I. Apostolikas N et al. Guidelines for pathology - supplement to European Guidelines for Quality Assurance in Mammography Screening. Pathologe 1997; 18; 71-88.
27. 27. Bànkfalvi À, Navabi B, Bier B, Böcker W. Jasani B, Schmid KW. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J. Pathol. 1994; 174; 223-228.
28. 28. Haynes BF, Liao H-X, Patton KL. The transmembrane hyaluronate receptor (CD44); multiple functions, multiple forms. Cancer Cells 1991; 3; 347-350.
29. 29. Terpe HJ. Stark H, Prehm P, Günthert U. CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 1994; 101; 79-89.
30. 30. GagliardiG, Kandemir O, Liu D et al. Changes in E-cadherin immunoreactivity in the adenoma-carcinoma sequence of the large bowel. Virchows Arch. 1995; 426; 149-154.
31. 31. Vessey CJ. Wilding J. Folarin N et al. Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J. Pathol. 1995; 176; 151-159.
32. 32. Jankowsky JA, Newham PM, Kandemir O, Hirano S, Takeichi M, Pignatelli M. Differential expressions of E-cadherin in normal, metaplastic and dysplastic oesophageal mucosa; a putative biomarker. Int. J. Oncol. 1994; 4; 441-448.
33. 33. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 12; 190-193.
34. 34. Bürger H, Böcker W, Otterbach F et al. Comparative genomic hybridization (CGH) of ductal carcinoma in situ of the breast -Evidence of multiple genetic pathways. J. Pathol. 1998 (accepted for publication).
35. 35. Liu D, Nigam AK, Lalani EN, Stamp GWH, Pignatelli M. Transfection of E-cadherin into a human colon carcinoma cell line induces differentiation and inhibits growth in vitro. Gut 1993; 34; 627 (abstract).
36. 36. Watabe M, Nagafuchi A, Tsukita S, Takeichi M. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J. Cell. Biol. 1994: 127; 247-256.
37. 37. Jones JL. Royall JE, Walker RA. E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma. Br. J. Cancer 1996; 74; 1237-1241.
38. 38. Lipponen P, Saarelainen E, Ji H, Aaltoma S. Syrjanen K. Expression of E-cadherin (E-Cad) as related to other prognostic factors and survival in breast cancer. J. Pathol. 1994; 174; 101-109.
39. 39. Friedrichs K, Franke F, Lisboa BW et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res. 1995; 55; 5424-5433.